70 articles found
Wisconsin will receive more than $80 million from the $7.4 billion Purdue Pharma and Sackler family settlement, with 70% directed to county and local governments for addiction treatment and prevention programs.
New JAMA Network Open research from Yale School of Medicine convenes 42 national experts to develop consensus guidelines for initiating medication-assisted treatment in hospitals as fentanyl transforms clinical protocols
Clinical trial shows semaglutide plus cognitive behavioral therapy significantly reduces alcohol consumption, offering new hope for treating alcohol use disorder with existing medications.
University of California Davis scientists create new amino acid-based compounds that activate serotonin receptors for mental health benefits without causing hallucinations, potentially revolutionizing addiction and depression therapy.
New NIH-funded research reveals that oral small-molecule GLP-1 drugs like orforglipron suppress hedonic feeding by modulating the central amygdala, opening potential pathways for treating substance use disorders.
New JAMA Network Open research from Yale brings together 42 national experts to develop consensus guidelines for initiating addiction medications in hospitals as fentanyl transforms treatment protocols
New data shows medication-assisted treatment for opioid use disorder reached 69% among Medicaid beneficiaries by 2023, yet 180-day treatment retention declined from 62.6% to 57.7%.
Colorado Opioid Abatement Council distributes infrastructure grants to 24 organizations, with demand exceeding available funding nearly four to one.
Historic expansion of Wisconsin's oldest women's addiction treatment facility addresses critical waitlist of 100+ people, funded by opioid settlement dollars and private philanthropy.
Maryland Attorney General Anthony Brown announces $90 million state allocation from $7.4 billion Purdue-Sackler settlement effective May 2026, with funds directed to treatment, prevention, and recovery services.
Kentucky reports fourth straight year of declining overdose deaths with 22.9% reduction in 2025, marking 50.8% decrease from 2021 peak as comprehensive state strategy shows sustained results.
Georgia's Opioid Crisis Abatement Trust opens applications for Year 3 funding, allocating $20 million to address addiction and overdose across the state.
Physicians publish urgent editorial urging federal action to protect access to addiction medications during climate emergencies after Hurricane Helene exposed critical gaps.
Trump administration's SAMHSA announces major policy reversal, banning federal funds for fentanyl test strips and sterile syringes while urging limitations on methadone and buprenorphine prescribing.
Milwaukee County reports dramatic 42.5% decline in drug overdose deaths since 2022, driven by harm reduction expansion, medication-assisted treatment, and $111 million opioid settlement investment.
West Virginia reports 48% drop in fatal drug overdoses, exceeding the national decline of 44%, as enforcement and public health efforts converge in the state hardest hit by the opioid crisis.
New data presented at ASAM 2026 shows extended-release buprenorphine (Sublocade) associated with lowest overdose rates among medication options and supports remission as meaningful treatment endpoint.
State regulations force daily clinic visits and limit take-home doses, making medication-assisted treatment more burdensome than federal standards require.
New JAMA Network Open study shows MOUD access among Medicaid beneficiaries rose from 60% to 69% between 2019-2023, with 45 states seeing increases.
In a region flooded with 17 million prescription opioids, proposed Medicaid work requirements and funding cuts threaten to dismantle the safety net that has helped hundreds achieve recovery from addiction.
Albertsons and Safeway parent company agrees to $773 million national settlement, with Oregon receiving up to $38.2 million over nine years to expand addiction and recovery services.
New research reveals 20% of US pharmacies block access to buprenorphine, with independent pharmacies and southern states showing significantly higher refusal rates for this life-saving opioid addiction medication.
JAMA research letter reveals 24.3% decline in long-term opioid therapy from 2015-2023, even as co-prescribing with gabapentinoids rises sharply, raising new safety concerns for chronic pain patients.
South Dakota distributes second round of transformative grants to 10 organizations, funding mobile street medicine, recovery coaching for incarcerated individuals, and primary care addiction training.
BMJ study of 2.5 million Medicaid births finds children exposed to buprenorphine in utero have no greater risk of ADHD, autism, or other neurodevelopmental disorders compared to methadone exposure.
JAMA Network Open study finds Medicaid expansion in eight states increased buprenorphine prescriptions by over 21%, with Oklahoma seeing 43% drop in overdose deaths.
New research in Journal of Psychiatric Research reveals individuals with opioid use disorder face 1.88 to 4.17 times greater odds of suicidal thoughts, with moderate cases showing highest attempt rates.
Iowa Department of Health and Human Services opens applications for up to $10 million in opioid settlement funds to expand behavioral health services and strengthen recovery systems across the state
New JAMA study shows states expanding Medicaid after 2018 saw sharp rises in buprenorphine prescriptions, but federal funding cuts could reverse gains.
New BMJ research finds semaglutide and similar medications associated with 14% reduced risk of developing substance use disorders and 50% fewer deaths among veterans already in treatment.
Michigan's MDHHS accepting applications through April 30 for loan repayment up to $30,000 to SUD providers as state confronts workforce shortage limiting treatment access for 1.3 million residents.
World Health Organization updates opioid dependence treatment recommendations, conditionally endorsing monthly injectable buprenorphine formulations as global treatment gap persists.
Congressional bill H.R. 5629 threatens to roll back SAMHSA's permanent methadone take-home flexibilities as Pew Charitable Trusts submits testimony defending COVID-era reforms that reduced travel burdens without increasing diversion or deaths.
NCDHHS awards federal block grant funding to twelve community organizations targeting rural areas, youth prevention, and criminal justice-involved populations as state battles 1.4 million struggling with substance use.
World Health Organization updates treatment guidelines adding monthly buprenorphine injections to methadone oral medication recommendations addressing epidemic killing three-quarters million people yearly
Deal flow in substance use disorder treatment hits six-year low as investors pull back amid quality concerns, Medicaid uncertainty, and volatile federal grants—leaving safety-net providers facing potential closures.
World Health Organization adds conditional recommendation for monthly and weekly buprenorphine injections, expanding evidence-based options for 61 million people using opioids non-medically worldwide.
University of Cincinnati launches one of nation's largest trials pairing weight-loss drugs with proven addiction medication to improve treatment retention and reduce cravings.
New research from Ohio University finds primary care physicians view opioid use disorder as more treatable than diabetes, yet only 8% have ever prescribed buprenorphine, creating treatment deserts in rural America.
World Health Organization adds conditional endorsement for long-acting injectable buprenorphine to global opioid dependence treatment guidelines April 2026, alongside continued strong recommendations for methadone and oral formulations.
Senator Patty Murray announces funding for Tacoma-Pierce County mobile medical services while highlighting successful pushback against Trump administration's proposed $2 billion SAMHSA grant terminations.
Georgia county awards settlement dollars to programs ranging from peer support to residential treatment as officials confront third-highest opioid death toll in the state.
American Society of Addiction Medicine releases first comprehensive update to youth substance use disorder treatment standards in over a decade, addressing telehealth, trauma-informed care, and medication access.
Congressional oversight hearing exposes chaotic federal response to addiction crisis as $2 billion in treatment grants remain uncertain and agency staff cut by half
Swedish registry analysis of 100,000 individuals finds GLP-1 medications reduce depression by 44%, anxiety by 38%, and substance use disorders by 47%.
New Nature Mental Health study finds combining low-dose ketamine with mindfulness training improves outcomes for people receiving buprenorphine treatment, opening door to psychedelic-assisted interventions
New Wisconsin Policy Forum report reveals dramatic expansion in MOUD access across state correctional facilities from 2021 to 2025, coinciding with substantial decline in overdose deaths.
CDCR documented over 7,000 overdose reversals since 2019 and became the only U.S. state prison system allowing incarcerated individuals to carry naloxone inside facilities.
SUPPORT Act allows pharmacists to prescribe addiction medication with 8 hours training. Maryland considers state legislation as federal pathway opens treatment access.
Opioid deaths fell 12% in Washington last year while innovative programs expanded access to life-saving treatment. But new Medicaid work requirements and federal funding cuts are already disrupting care.
Survey of 212 U.S. jails, prisons, and detention centers finds stark regional and facility-type disparities in MOUD access, with post-release mortality 40 times higher than national average.
Workit Health's evidence-based virtual care model delivers 62% rural retention at three months—more than double competing programs—with peer-reviewed studies in JAMA Network Open showing perfect buprenorphine adherence among participants.
First randomized trial testing extended-release buprenorphine in pregnancy finds higher abstinence rates and fewer serious adverse events compared to standard sublingual treatment.
New federal data reveals historic decline in opioid deaths across all demographics, driven by expanded naloxone access, weaker fentanyl supply, and medication treatment—though Arizona and four other states buck the trend.
Brandeis University economic analysis shows two pharmacy-based methadone models generate positive returns of $2.64 and $3.53 per dollar spent over three years while addressing treatment deserts in 80% of U.S. counties.
Somerset County commissioners chose to protect a jail Sublocade program with zero overdose deaths over prevention services as opioid settlement funds run short.
ACLU challenges West Virginia's 2007 moratorium on methadone clinics, arguing the state's unique restriction violates disability law while forcing 54,000 residents with opioid use disorder to navigate impossible treatment logistics.
A new survey of 212 jails and prisons finds only 58% provide FDA-approved medications for opioid use disorder, with stark regional disparities and treatment gaps putting released inmates at 40-times-higher overdose risk.
Senate Bill 2185 passed committee and would mandate MAT screening and access in all Illinois prisons, funded by opioid settlements, following a Kane County program that cut overdose deaths by 89%.
NIH-funded trial finds pregnant patients receiving weekly extended-release buprenorphine injections achieved significantly higher rates of opioid abstinence with fewer serious adverse events than those on sublingual buprenorphine.
New research shows patients adherent to extended-release buprenorphine injections had $15,017 lower annual costs and fewer emergency visits than those using other opioid use disorder medications.
New study finds NET Device reduces opioid and stimulant use for 3 months post-treatment, offering hope for polysubstance addiction amid no approved medications for stimulants
VA study of 600,000 patients finds GLP-1 medications like Ozempic reduce substance use disorder risk by 15-20%, suggesting a common biological pathway underlying all addictions.
New CDC data reveals West Virginia and Virginia achieved the steepest opioid death declines in America, with drops approaching 49% and outpacing the national 44% reduction.
Weill Cornell research shows state laws eliminating insurance prior authorization for buprenorphine don't significantly improve 180-day retention rates, highlighting need for broader policy interventions.
Civil rights lawsuit alleges Missouri DOC and Centurion Health deny life-saving medication to prisoners with opioid use disorder, despite $7M in settlement funds and rampant drug availability.
Washington University analysis of 600,000+ VA patients finds GLP-1s tied to 50% reduction in drug-related deaths and lower risk across alcohol, opioid, cocaine, and nicotine use disorders.
In a landmark policy shift, the FDA announced it will approve new drugs based on a single rigorous trial plus confirmatory evidence—a change that could accelerate development of therapies for opioid use disorder, alcohol addiction, and stimulant dependence.
The Food and Drug Administration moves forward with controversial regulations to limit common painkillers, sparking national debate over balancing opioid crisis response with patient access to pain management.
New federal rules allow providers to prescribe six-month supply of buprenorphine via audio-only telehealth for opioid use disorder treatment, eliminating pandemic-era restrictions while implementing safeguards.